

BIOGEN IDEC INC.  
Form 8-K  
February 27, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549  
FORM 8-K  
CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **February 27, 2008**

**Biogen Idec Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**0-19311**

(Commission File Number)

**33-0112644**

(IRS Employer Identification No.)

**14 Cambridge Center, Cambridge, Massachusetts**

(Address of Principal Executive Offices)

**02142**

(Zip Code)

**(617) 679-2000**

(Registrant's Telephone Number, Including Area Code)

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))x
-

**TABLE OF CONTENTS**

Item 8.01. Other Events.

Item 9.01. Financial Statements and Exhibits.

**SIGNATURES**

Ex-99.1 Dear Healthcare Professional letter, dated February 2008, issued by the Registrant Elan

---

**Table of Contents**

**Item 8.01. Other Events.**

As previously disclosed, clinically significant liver injury has been reported in patients treated with TYSABRI in the post-marketing setting. Biogen Idec Inc. (the Registrant ) and its TYSABRI collaboration partner, Elan Corporation plc ( Elan ) have issued a letter to healthcare professionals describing these risks. A copy of the letter was posted today on the U.S. Food and Drug Administration 's website and is attached as exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

(d) *Exhibits.*

Exhibit 99.1 Dear Healthcare Professional letter, dated February 2008, issued by the Registrant and Elan.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Biogen Idec Inc.**

Dated: February 27, 2008

By: /s/ Robert A. Licht  
Name: Robert A. Licht  
Title: Vice President and Assistant  
Secretary